The heart-protective effects of a novel SGLT2 inhibitor (NSI) in diabetic cardiomyopathy, beyond blood sugar control is of interest.NSI was compared with dapagliflozin and Terminalia Arjuna (TA) using preclinical models. This evidence concerns the gene SLC5A2 and diabetic cardiomyopathy.